{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:37:04Z","timestamp":1780688224303,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.endien.2026.501713","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:50:51Z","timestamp":1770295851000},"page":"501713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study"],"prefix":"10.1016","volume":"73","author":[{"given":"Javier","family":"Lago Garma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil Mouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareth","family":"Rodr\u00edguez Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaia","family":"D\u00edaz Trastoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Santamar\u00eda Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"P\u00e9rez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"D\u00edaz Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Palmeiro Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Pinal Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Prieto Tenreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"S\u00e1nchez Sobrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tejera P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pita Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar Taibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Vidal Casariego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2026.501713_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endien.2026.501713_bib0010","series-title":"Encuesta Europea de Salud en Espa\u00f1a 2020: Informaci\u00f3n, evoluci\u00f3n y principales resultados","year":"2021"},{"key":"10.1016\/j.endien.2026.501713_bib0015","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"issue":"Suppl 1","key":"10.1016\/j.endien.2026.501713_bib0020","first-page":"S1","article-title":"Standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2026.501713_bib0025","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.endien.2026.501713_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-021-00713-9","article-title":"Advances in GLP-1 treatment: focus on oral semaglutide","volume":"13","author":"Eliaschewitz","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.endien.2026.501713_bib0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pcd.2018.11.009","article-title":"Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: an inception cohort study","volume":"13","author":"Torre","year":"2019","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.endien.2026.501713_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049130","article-title":"Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review","volume":"11","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.endien.2026.501713_bib0045","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/dom.15431","article-title":"Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: a nationwide multicentre retrospective observational study (ENDO2S-RWD)","volume":"26","author":"Moreno-P\u00e9rez","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2026.501713_bib0050","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s13300-020-00985-w","article-title":"Effect of orally administered semaglutide versus dulaglutide on diabetes-related quality of life in Japanese patients with type 2 diabetes: the PIONEER 10 randomized, active-controlled trial","volume":"12","author":"Ishii","year":"2021","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.endien.2026.501713_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.endien.2026.501713_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2026.501713_bib0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2026.501713_bib0070","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2026.501713_bib0075","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/dom.15493","article-title":"Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: a multicentre, prospective real-world study (PIONEER REAL Canada)","volume":"26","author":"Jain","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2026.501713_bib0080","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","article-title":"Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes","volume":"30","author":"Matza","year":"2021","journal-title":"Qual Life Res"},{"issue":"9-a Suppl","key":"10.1016\/j.endien.2026.501713_bib0085","first-page":"S30","article-title":"Health-related quality of life assessments with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus","volume":"24","author":"Billings","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.endien.2026.501713_bib0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03320906","article-title":"Validaci\u00f3n del cuestionario \u201cDiabetes treatment satisfaction questionnaire\u201d (DTSQ) en la poblaci\u00f3n espa\u00f1ola","volume":"3","author":"Gomis","year":"2006","journal-title":"PharmacoEconomics Spanish Research Articles"},{"key":"10.1016\/j.endien.2026.501713_bib0095","first-page":"79","article-title":"The Spanish version of EuroQol: a description and its applications. European Quality of Life scale","volume":"112","author":"Badia","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.endien.2026.501713_bib0100","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/dom.14039","article-title":"Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)","volume":"22","author":"J\u00f3dar","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2026.501713_bib0105","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1111\/dom.16523","article-title":"PIONEER REAL Spain: a multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes","volume":"27","author":"Delgado \u00c1lvarez","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2026.501713_bib0110","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1111\/dom.15145","article-title":"The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): final patient-reported outcomes at 24 months","volume":"25","author":"Boye","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2026.501713_bib0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pcd.2018.11.009","article-title":"Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study","volume":"13","author":"Torre","year":"2019","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.endien.2026.501713_bib0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.endien.2026.501713_bib0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2026.501713_bib0130","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2026.501713_bib0135","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PioNEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2026.501713_bib0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2026.501713_bib0145","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. La AEMPS emite recomendaciones para evitar o paliar problemas de suministro con los medicamentos an\u00e1logos del GLP-1. 2022. Referencia ICM (CONT), 12\/2022."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018026000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018026000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:30:14Z","timestamp":1772872214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018026000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2530018026000132"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2026.501713","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2026.501713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2025.501713","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501713"}}